1. Signaling Pathways
  2. Epigenetics
  3. Histone Methyltransferase
  4. EHMT2/G9a/KMT1C Isoform

EHMT2/G9a/KMT1C

 

EHMT2/G9a/KMT1C Related Products (11):

Cat. No. Product Name Effect Purity
  • HY-101925
    CM-272
    Inhibitor 99.27%
    CM-272 is a first-in-class, potent, selective, substrate-competitive and reversible dual G9a/DNA methyltransferases (DNMTs) inhibitor with antitumor activities.
  • HY-10929
    UNC0224
    Inhibitor 99.31%
    UNC0224 is a potent and selective histone methyltransferase G9a inhibitor with a Ki of 2.6 nM, an IC50 of 15 nM and a Kd of 23 nM.
  • HY-13807
    UNC0646
    Inhibitor 99.82%
    UNC0646 is a potent and selective histone methyltransferase G9a inhibitor with an IC50 of 6 nM.
  • HY-13808
    UNC 0631
    Inhibitor 99.35%
    UNC 0631 is a potent histone methyltransferase G9a inhibitor with an IC50 of 4 nM.
  • HY-10930
    UNC0321
    Inhibitor 99.43%
    UNC0321 is a potent and selective histone methyltransferase G9a inhibitor with a Ki of 63 pM and with assay-dependent IC50 values of 6-9 nM.
  • HY-150510
    MS8511
    Inhibitor
    MS8511 is a selective G9a/GLP covalent irreversible inhibitor by targeting a cysteine residue at the substrate binding site, with IC50 values of 100 nM (G9a) and 140 nM (GLP), and Kd values of 44 nM (G9a) and 46 nM (GLP).
  • HY-15647
    BRD9539
    Inhibitor 99.20%
    BRD9539 is a histone methyltransferase G9a inhibitor with an IC50 of 6.3 μM.
  • HY-111904
    EHMT2-IN-2
    Inhibitor ≥99.0%
    EHMT2-IN-2 is a potent EHMT inhibitor, with IC50s of all <100 nM for EHMT1 peptide, EHMT2 peptide and cellular EHMT2.
  • HY-111778
    EHMT2-IN-1
    Inhibitor 99.90%
    EHMT2-IN-1 is a potent EHMT inhibitor, with IC50s of all <100 nM for EHMT1 peptide, EHMT2 peptide and cellular EHMT2.
  • HY-111544
    EML741
    Inhibitor
    EML741 is a histone lysine methyltransferase G9a/GLP inhibitor, with an IC50 of 23 nM, Kd of 1.13 μM for G9a.
  • HY-133031
    CSV0C018875
    Inhibitor
    CSV0C018875 is a quinoline-based EHMT2/G9a inhibitor.